Substantial progress in the field of psychedelic therapy has now been achieved in Canada.
On Thursday, Serenus Global Inc. announced that it had obtained its first Health Canada controlled substance reseller license. The new license will allow the company to possess, produce, sell, transport, import, export and deliver psilocybin and psilocin in accordance with a series of regulations dictated by the Canadian government.
The Company will engage in its psychoactive mushroom businesses through its wholly owned subsidiary, Conscious Compounds Inc.
Read more: Optimi Health partners with patient advocate to launch new psilocybin product
Read more: Sisters in Psychedelics Hosts Inaugural Summit in Vancouver in September
In addition to the production of psilocybin, Serenus is a company specializing in the production of coffee, cannabis and an assortment of non-psychoactive edible mushrooms for health and well-being.
The company will begin psilocybin operations in a “purpose-built, EU GMP-compliant production and research facility” in Calgary, Alberta. Serenus plans to expand its domestic and international reach through controlled substance production, research and development at this facility.
The company also says it will continue to expand its knowledge of psilocybin mushrooms through clinical trials and further studies.
“From day one, Serenus’ mission has remained focused on cultivating and producing controlled substances of consistent high quality that are safe to use and that will provide our customers with options for new treatments in the areas of depression, PTSD, substance abuse control and mental health,” said Dave Auger, COO of Serenus Global Inc.
“We are proud to become an official licensee for the production of psychedelic mushrooms in Canada and demonstrate our team’s ability to navigate the regulatory landscape. We look forward to immediately beginning genetic and product development,” Auger added.
Like Mugglehead on Facebook